Funding Opportunities

NIH- Research Answers to NCI’s Provocative Questions – Group A (R21)- RFA-CA-13-017

due: 20-06-2014 Research NIH RFA-CA-13-017 Faculty required
List of PQs for this FOA: Group A Each application must address one and only one specific PQ from Group A, exactly as defined in this FOA. PQA1: (Rewritten for 2013) How do decision-making processes influence habitual behaviors, and how can that knowledge be used to design strategies that lead to adoption and maintenance of behaviors that reduce cancer risk? PQA2: (Retained from 2012) How does the level, type, and/or duration of physical activity influence cancer risk and prognosis? PQA3: (Rewritten for 2013) What biological mechanisms influence susceptibility to cancer risk factors at various stages of life? PQA4: (Rewritten for 2013) For tumors that arise from a pre-malignant field, what properties of cells in this field can be used to design strategies to inhibit the development of future tumors?

NIH – Research Answers to NCI’s Provocative Questions- Group B (R01)- RFA-CA-13-018

due: 20-06-2014 Research NIH RFA-CA-13-018 Faculty required
List of PQs for this FOA: Group B Each application must address one and only one specific PQ from Group B, exactly as defined in this FOA. PQB1: (Retained from 2012) Why do second, independent cancers occur at higher rates in patients who have survived a primary cancer than in a cancer-naïve population? PQB2: (Rewritten for 2013) What molecular and cellular events in the tumor microenvironment (for example, the local immune response) determine if a tumor at the earliest stages of malignant transformation is eliminated, stimulated for further development, or made indolent? PQB3: (Rewritten for 2013) What mechanisms initiate or sustain cancer cachexia, and can we target them to extend lifespan and quality of life for cancer patients? PQB4: (New for 2013) What methods can be devised to characterize the functional state of individual cells within a solid tumor?

NIH – Research Answers to NCI’s Provocative Questions – Group C (R01)- RFA-CA-13-020

due: 20-06-2014 Research NIH RFA-CA-13-020 Faculty required
List of PQs for this FOA: Group C Each application must address one and only one specific PQ from Group C, exactly as defined in this FOA. PQC1: (Rewritten for 2013) What properties of pre-cancerous lesions or their microenvironment predict the likelihood of progression to malignant disease? PQC2: (Retained from 2012) What molecular or cellular events establish tumor dormancy after treatment and what leads to recurrence? PQC3: (New for 2013) How do variations in tumor-associated immune responses among patients from distinct well-defined populations, such as various racial/ethnic or age groups, contribute to differences in cancer outcomes? PQC4: (New for 2013) What in vivo imaging methods can be developed to portray the "cytotype" of a tumor — defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment?

NIH- Research Answers to NCI’s Provocative Questions – Group C (R21)- RFA-CA-13-021

due: 20-06-2014 Research NIH RFA-CA-13-021 Faculty required
List of PQs for this FOA: Group C Each application must address one and only one specific PQ from Group C, exactly as defined in this FOA. PQC1: (Rewritten for 2013) What properties of pre-cancerous lesions or their microenvironment predict the likelihood of progression to malignant disease? PQC2: (Retained from 2012) What molecular or cellular events establish tumor dormancy after treatment and what leads to recurrence? PQC3: (New for 2013) How do variations in tumor-associated immune responses among patients from distinct well-defined populations, such as various racial/ethnic or age groups, contribute to differences in cancer outcomes? PQC4: (New for 2013) What in vivo imaging methods can be developed to portray the "cytotype" of a tumor — defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment?

NIH- Research Answers to NCI’s Provocative Questions – Group D (R01) – RFA-CA-13-022

due: 20-06-2014 Research NIH RFA-CA-13-022 Faculty required
List of PQs for this FOA: Group D Each application must address one and only one specific PQ from Group D, exactly as defined in this FOA. PQD1: (Retained from 2012) What molecular properties make some cancers curable with conventional chemotherapy? PQD2: (New for 2013) What features of standard-of-care therapies enhance or inhibit the efficacy of immunotherapy? PQD3: (New for 2013) Do tumors evolve common features that could act as new therapeutic targets when they metastasize to the same secondary site? PQD4: (New for 2013) What are the mechanistic bases for differences in cancer drug metabolism and toxicity at various stages of life?